XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:        
Total revenue $ 143,823 $ 108,761 $ 444,730 $ 319,916
Cost of revenue:        
Total cost of revenue 59,248 47,916 175,338 129,848
Gross profit 84,575 60,845 269,392 190,068
Operating expenses:        
Research, development and clinical trials 15,260 14,266 48,354 39,504
Selling, general and administrative 46,015 42,656 133,728 121,712
Total operating expenses 61,275 56,922 182,082 161,216
Income from operations 23,300 3,923 87,310 28,852
Other income (expense):        
Interest expense (3,491) (3,617) (10,428) (10,838)
Interest income and other income (expense) 3,222 3,939 9,007 10,777
Total other income (expense), net (269) 322 (1,421) (61)
Income before income taxes 23,031 4,245 85,889 28,791
(Provision) benefit for income taxes 1,288 (29) (981) (184)
Net income $ 24,319 $ 4,216 $ 84,908 $ 28,607
Net income per share, basic $ 0.71 $ 0.13 $ 2.5 $ 0.86
Net income per share, diluted $ 0.66 $ 0.12 $ 2.28 $ 0.81
Weighted average common shares outstanding, basic 34,112,452 33,441,394 33,917,006 33,108,253
Weighted average common shares outstanding, diluted 40,748,023 35,683,952 40,410,208 35,218,756
Net product revenue [Member]        
Revenue:        
Total revenue $ 87,677 $ 65,861 $ 272,011 $ 198,918
Cost of revenue:        
Total cost of revenue 18,687 13,246 54,420 41,800
Service Revenue [Member]        
Revenue:        
Total revenue 56,146 42,900 172,719 120,998
Cost of revenue:        
Total cost of revenue $ 40,561 $ 34,670 $ 120,918 $ 88,048